IDH2 and plasma cell myeloma: Although the use of IDH 1/2 inhibitors, ivosidenib and enasidenib, have found success in AML among the approximately 16% of IDH-mutated patients, in multiple myeloma IDH mutations are only seen in 0.5% (103, 104).